Hormonal
Gut peptides (specifically GLP-1 and GIP) modulate hedonic feeding and reward-seeking behavior, extending beyond homeostatic satiety, which provides a mechanism for the significant weight loss observed with GLP-1/GIP receptor agonists.
Your brain's reward system for food is biologically regulated by hormones from your gut. Medications like GLP-1 agonists work not just by making you feel full, but by dampening the brain's reward response to food cues, making it easier to resist high-calorie foods without relying solely on willpower.
It has now become clear that the effect of gut peptide receptor activation extends beyond simple homeostatic food intake control; hedonic mechanisms governing appetite are also modulated.
Why this rating
The paper is a comprehensive review citing numerous human clinical trials (e.g., Wilding et al. 2021) and mechanistic animal studies.
Source
Gut peptide regulation of food intake - evidence for the modulation of hedonic feeding.
Orla Woodward et al. · Apollo (University of Cambridge) · 2021
DOI 10.17863/cam.74301
More from this paper
- Ghrelin, the 'hunger hormone', directly stimulates reward pathways in the brain (VTA and NAc) to increase motivation and willingness to work for food, particularly palatable/high-fat foods.Good
- Cholecystokinin (CCK) attenuates reward-related signaling and motivation for food, acting as a satiety signal that can block the acquisition of conditioned place preference associated with rewarding stimuli.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →